Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger Sells 5,739 Shares

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Edwards Lifesciences Stock Down 0.1 %

Shares of EW traded down $0.11 during mid-day trading on Tuesday, hitting $76.09. 1,589,465 shares of the company's stock were exchanged, compared to its average volume of 4,464,341. The company has a market cap of $44.87 billion, a PE ratio of 10.99, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a 50-day simple moving average of $72.78 and a 200 day simple moving average of $69.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter worth $30,000. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth $30,000. Finally, Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth $32,000. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on EW shares. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Daiwa America downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 30th. Finally, Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.